Joseph G. Jurcic

Columbia University Irving Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.

Year:

2025

Comprehensive list of clinically relevant drugs screened in cell lines (not all were available at time of study). The list is divided into three sections, including one with FDA approved antineoplastics, one with experimental antineoplastics in clinical trials, and one with non-antineoplastics and tool compounds selectively screened when demonstrating an EC50

Year:

2025

Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.

Year:

2025

Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.

Year:

2024

Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.

Year:

2024

Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.

Year:

2024

Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.

Year:

2024

Comprehensive list of clinically relevant drugs screened in cell lines (not all were available at time of study). The list is divided into three sections, including one with FDA approved antineoplastics, one with experimental antineoplastics in clinical trials, and one with non-antineoplastics and tool compounds selectively screened when demonstrating an EC50

Year:

2024

Comprehensive list of clinically relevant drugs screened in cell lines (not all were available at time of study). The list is divided into three sections, including one with FDA approved antineoplastics, one with experimental antineoplastics in clinical trials, and one with non-antineoplastics and tool compounds selectively screened when demonstrating an EC50

Year:

2024

Purpose: The anti-CD33 antibody lintuzumab has modest activity against acute myeloid leukemia (AML). To increase its potency, lintuzumab was conjugated to actinium-225 (225Ac), a radionuclide yielding 4 α-particles. This first-in-human, phase I trial was conducted to determine the safety, pharmacology, and biological activity of 225Ac-lintuzumab. Patients and Methods: Eighteen patients (median age, 64 years; range, 45–80) with relapsed or refractory AML received a single infusion of 225Ac-lintuzumab at activities of 18.5 to 148 kBq/kg. Results: The maximum tolerated dose was 111 kBq/kg. Dose-limiting toxicities included myelosuppression lasting > 35 days in one patient receiving 148 kBq/kg and death from sepsis in two patients treated with 111 and 148 kBq/kg. Myelosuppression was the most common toxicity. Significant extramedullary toxicities were limited to transient grade 3 liver function abnormalities. Pharmacokinetics were determined by gamma counting serial whole blood, plasma, and urine samples at energy windows for the 225Ac daughters, francium-221 and bismuth-213. Two-phase elimination kinetics were seen with mean plasma t1/2 − α and t1/2 − β of 1.9 and 38 hours, respectively. Peripheral blood blasts were eliminated in 10 of 16 evaluable patients (63%) but only at doses of ≥ 37 kBq/kg. Bone marrow blasts were reduced in 10 of 15 evaluable patients (67%), including 3 patients with marrow blasts ≤ 5% and one patient with a morphologic leukemia-free state. Conclusions: Therapy for AML with the targeted α-particle generator 225Ac-lintuzumab was feasible with an acceptable safety profile. Elimination of circulating blasts or reductions in marrow blasts were observed across all dose levels.

Year:

2022

Collaborators (23)

Prabhjot Mundi

Assistant Professor

Columbia University Irving Medical Center

UNITED STATES
View details

Peter Sims

Assistant Professor

Columbia University Irving Medical Center

UNITED STATES
View details

Hanina Hibshoosh

Professor of pathology at CUIMC

Columbia University

UNITED STATES
View details

Guy M. McKhann

Florence Irving Associate Professor of Neurological Surgery

Columbia University Irving Medical Center

UNITED STATES
View details

Ana Tergas

Rutgers, The State Univ. of NJ

UNITED STATES
View details

Kenneth Olive

Assistant Dean of Graduate Curricula and Associate Professor of Medicine

Columbia University Irving Medical Center

UNITED STATES
View details

Guarionex Joel DeCastro

Associate Professor

Columbia University

UNITED STATES
View details

Jason D. Wright

-

UNITED STATES
View details

Andrew Kung

Chair

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Mariano Alvarez

Chief Scientific Officer

KweHealth, LLC

UNITED STATES
View details

Gary K. Schwartz

Case Western Reserve University

UNITED STATES
View details

Andrew Lassman

Chief, Neuro-Oncology Division

Columbia University Irving Medical Center

UNITED STATES
View details

Dawn L. Hershman

Columbia University Irving Medical Center

UNITED STATES
View details

Kevin Kalinsky

Emory University

UNITED STATES
View details

Katherine Crew

Professor

Columbia University Irving Medical Center

UNITED STATES
View details

Alfred I. Neugut

-

UNITED STATES
View details

Daniel Diolaiti

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Michael Kluger

Professor of Surgery

NYU Langone Health

UNITED STATES
View details

Andrea Califano

Columbia University Irving Medical Center

UNITED STATES
View details

Eugene Douglass

Assistant Professor

University of Georgia

UNITED STATES
View details

Catherine Shu

Columbia University Irving Medical Center

UNITED STATES
View details

Melissa K. Accordino

Columbia University

UNITED STATES
View details

Jeffrey Bruce

NewYork-Presbyterian Hospital/Columbia University Irving Medical Center

UNITED STATES
View details